
Daniel Taussky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/127945/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 57.e15-57.e23.	0.8	7
2	A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. Canadian Urological Association Journal, 2022, 16, .	0.3	3
3	Prevalence and Risk Factors of QTc Prolongation in Prostate Cancer Patients Undergoing Brachytherapy. Cancer Investigation, 2022, , 1-9.	0.6	0
4	Biochemical failure-rate and preservation of erectile function after prostate seed brachytherapy in early-onset prostate cancer Canadian Journal of Urology, 2022, 29, 10986-10991.	0.0	0
5	The interaction between inflammation, urinary symptoms and erectile dysfunction in earlyâ€stage prostate cancer treated with brachytherapy. Andrologia, 2021, 53, e14070.	1.0	1
6	The one hundred most cited publications in prostate brachytherapy. Brachytherapy, 2021, 20, 611-623.	0.2	1
7	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	1.2	3
8	PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study. Brachytherapy, 2021, 20, 1090-1098.	0.2	10
9	Do Women Have Equal Chances for an Academic Career in Radiation Oncology in Canada? A Comparison With Related Specialties. Advances in Radiation Oncology, 2020, 5, 313-317.	0.6	2
10	Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer. Brachytherapy, 2020, 19, 222-227.	0.2	9
11	Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate. Cells, 2020, 9, 2153.	1.8	2
12	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal, 2020, 15, 181-186.	0.3	13
13	Active surveillance before radiotherapy — outcome and predictive factors for multiple biopsies before treatment. Canadian Urological Association Journal, 2020, 15, E36-E40.	0.3	0
14	Impact of diabetes and metformin use on prostate cancer. Scandinavian Journal of Urology, 2020, 54, 508-509.	0.6	1
15	The relationship between preâ€radiation therapy testosterone levels and prostate cancer aggressiveness. Andrologia, 2020, 52, e13731.	1.0	1
16	Twitter. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 442-445.	0.6	24
17	A Portrait of Current Radiation Oncology Twitter Influencers. Cureus, 2020, 12, e10838.	0.2	3
18	ls pelvic prophylactic radiotherapy in prostate cancer just right?. Translational Andrology and Urology, 2020, 9, 2296-2298.	0.6	2

DANIEL TAUSSKY

#	Article	IF	CITATIONS
19	A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. Advances in Radiation Oncology, 2019, 4, 631-640.	0.6	21
20	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation Oncology, 2019, 14, 60.	1.2	18
21	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. Canadian Urological Association Journal, 2019, 14, E173-E179.	0.3	1
22	A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation—Impact on biochemical failure. Brachytherapy, 2018, 17, 277-282.	0.2	5
23	Pre-radiotherapy PSA progression is aÂnegative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors. Strahlentherapie Und Onkologie, 2018, 194, 17-22.	1.0	0
24	Impact of adipose tissue on prostate cancer aggressiveness – analysis of a high-risk population. Hormone Molecular Biology and Clinical Investigation, 2018, 36, .	0.3	8
25	Pelvic radiotherapy in prostate cancer: an unresolved question. Lancet Oncology, The, 2018, 19, 1428-1429.	5.1	4
26	Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2Âng/mL. Brachytherapy, 2018, 17, 794-798.	0.2	2
27	Fusion of Intraoperative Transrectal Ultrasound Images with Post-implant Computed Tomography and Magnetic Resonance Imaging. Cureus, 2018, 10, e2394.	0.2	0
28	Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database. Canadian Journal of Urology, 2018, 25, 9509-9515.	0.0	8
29	Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy. Brachytherapy, 2017, 16, 348-352.	0.2	4
30	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.3	16
31	Authors' response. Brachytherapy, 2017, 16, 655.	0.2	0
32	A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer. Targeted Oncology, 2017, 12, 695-701.	1.7	6
33	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Canadian Urological Association Journal, 2017, 11, 94.	0.3	0
34	ls intraoperative real-time dosimetry in prostate seed brachytherapy predictive of biochemical outcome?. Journal of Contemporary Brachytherapy, 2017, 4, 304-308.	0.4	7
35	Functional and oncological outcomes of salvage external beam radiotherapy following robot-assisted radical prostatectomy in a Canadian cohort. Canadian Urological Association Journal, 2017, 12, 45-9.	0.3	1
36	Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer Journal of Clinical Oncology, 2017, 35, 96-96.	0.8	0

DANIEL TAUSSKY

#	Article	IF	CITATIONS
37	A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer. Canadian Urological Association Journal, 2016, 10, 246.	0.3	9
38	Magnetic resonance imaging for prostate bed radiotherapy planning: An inter―and intraâ€observer variability study. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 255-259.	0.9	18
39	Impact of visceral fat volume and fat density on biochemical outcome after radical prostatectomy and postoperative radiotherapy. Hormone Molecular Biology and Clinical Investigation, 2016, 26, 173-178.	0.3	6
40	Seed loss in prostate brachytherapy. Strahlentherapie Und Onkologie, 2016, 192, 305-311.	1.0	6
41	CAPRA-S predicts outcome for adjuvant and salvage EBRT after radical prostatectomy. Canadian Urological Association Journal, 2016, 10, 132.	0.3	4
42	Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus, 2016, 8, e935.	0.2	9
43	Postoperative radiotherapy after prostatectomy: whom to treat. Finally light at the end of the tunnel?. Canadian Journal of Urology, 2016, 23, 8576.	0.0	0
44	Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices. Canadian Urological Association Journal, 2015, 9, 608.	0.3	3
45	Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapy. Brachytherapy, 2015, 14, 329-333.	0.2	6
46	Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer, 2015, 15, 594.	1.1	49
47	Association of neutrophil count with overall survival in localized prostate cancer Journal of Clinical Oncology, 2015, 33, 121-121.	0.8	0
48	The Quadrella: A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy. Radiotherapy and Oncology, 2014, 111, 110-113.	0.3	5
49	The <scp>C</scp> ancer of the <scp>P</scp> rostate <scp>R</scp> isk <scp>A</scp> ssessment (<scp>CAPRA</scp>) score predicts biochemical recurrence in intermediateâ€risk prostate cancer treated with external beam radiotherapy (<scp>EBRT</scp>) dose escalation or lowâ€dose rate (<scp>LDR</scp>) brachytherapy, BlU International, 2014, 114, 865-871.	1.3	13
50	Analysis of the Cancer of the Prostate Risk Assessment to Predict for Biochemical Failure After External Beam Radiotherapy or Prostate Seed Brachytherapy. Urology, 2014, 84, 629-633.	0.5	12
51	Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy. Radiation Oncology, 2014, 9, 93.	1.2	7
52	Preoperative Intensity Modulated Radiation Therapy for Retroperitoneal Sarcoma. Technology in Cancer Research and Treatment, 2014, 13, 211-216.	0.8	14
53	The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology, 2012, 36, e137-e141.	0.8	3
54	Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy, 2012, 11, 452-456.	0.2	23

DANIEL TAUSSKY

#	Article	IF	CITATIONS
55	Urethra-Sparing, Intraoperative, Real-Time Planned, Permanent-Seed Prostate Brachytherapy: Toxicity Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 81, e377-e383.	0.4	32
56	Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncológica, 2011, 50, 555-562.	0.8	14
57	Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer. Cancer, 2010, 116, 5650-5658.	2.0	18
58	Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?. Canadian Journal of Urology, 2009, 16, 4599-600.	0.0	5
59	Does Timing of Androgen Deprivation Influence Radiation-Induced Toxicity? A Secondary Analysis of Radiation Therapy Oncology Group Protocol 9413. Urology, 2008, 72, 1125-1129.	0.5	11
60	Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: An exploratory outcomes analysis. International Journal of Radiation Oncology Biology Physics, 2005, 62, 684-689.	0.4	13
61	Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head and Neck, 2005, 27, 182-186.	0.9	73